Siggi Olafsson

Chief Executive Officer

  • Appointed: 2018
  • Joined Hikma: 2018
  • Nationality: Icelandic

Skills and Experience: Siggi has significant international experience in the pharmaceutical industry. From 2012 to 2014, he was President of Actavis, which was then acquired by Teva Pharmaceuticals where he was appointed President and Chief Executive Officer of the Global Generic Medicines Group until 2017. Prior to this, he was Executive Vice President, Global Generics, at Actavis plc (Watson) from 2010 to 2012; and CEO of the Actavis Group from 2008 to 2010. From 2003 to 2008, he held positions of increasing responsibility within the Actavis Group, including Deputy CEO, Vice President of Corporate Development and CEO of Actavis Inc. U.S. From 1998 to 2003, he held positions of increasing responsibility with Pfizer’s Global R&D organization in the U.K. and U.S. From 1994 to 1998, he served as Head of Drug Development for Omega Farma in Iceland. He currently serves as a member of the board of directors for Elucida Oncology and Pfenex.

M.S. in pharmacy (Cand Pharm) from the University of Iceland, Reykjavik.

Other Appointments: Siggi is an independent director of Pfenex Inc., a biologics company listed on the New York Stock Exchange and a director at Elucida Oncology Inc. and an executive trustee of the American-Scandinavian Foundation.

Committee memberships: CRE Committee